Saturday, April 22, 2017

Hepatitis C Generic therapies ‘overtook’ branded DAAs in 2016

Generic therapies ‘overtook’ branded DAAs in 2016

AMSTERDAM — A presenter at today’s viral hepatitis session at the International Liver Congress called on the clinical community to push the envelope in using generic direct-acting antiviral therapies.

Despite the presence of curative therapies, James Freeman, MD, of GP2U Telehealth FixHepC in Hobart, Australia, noted that every 45 seconds, another patient dies of hepatitis C. “It remains one of the greatest tragedies of modern time that these drugs are not being deployed on a mass scale,” he said, comparing the cost of Daklinza (daclatasvir, Bristol-Myers Squibb) to that of diamonds.

“We have seen great improvements in pricing,” Freeman said. “The price of generics is approaching the cost of production.”

He described 2016 as a “big year” for generics. “There was a lot of protesting about prices,” he said. “But generic DAA’s overtook branded medications. Bioequivalence has been demonstrated.”

Continue reading....

Meeting Coverage Healio
International Liver Congress

International Liver Congress™ 2017
Updates On This Blog

No comments:

Post a Comment